Livzon Pharmaceutical Group Inc. and its controlling subsidiary, Shanghai Livzon Pharmaceutical Manufacturing Co. Ltd. received the "Notice of Acceptance" (acceptance No.: CXHS2300072) issued by the National Medical Products Administration (the "NMPA"), which accepted the application for the registration and marketing authorization of Triptorelin Acetate Microspheres for Injection (Zhu She Yong Cu Suan Qu Pu Rui Lin Wei Qiu) against endometriosis. Common name of drug: Triptorelin Acetate Microspheres for Injection; English Name: Triptorelin Acetate Microspheres for Injection; Dosage form: injection; Strength: 3.75mg (based on C64H82N18O13); Application: registration and marketing authorization for domestically manufactured drug; Registration classification: Class 2.4 chemical drug; Review conclusion of the notice of acceptance: It has been determined after review that the application was accepted in accordance with the provision of Article 32 of the "Administrative Licensing Law of the PRC.

Triptorelin Acetate Microspheres for Injection is a high-end long-acting microsphere preparation independently developed by the Company, and was approved for market launch in May 2023. It is applicable to "prostate cancer patients who need androgen deprivation therapy". For details, please refer to the ANNOUNCEMENT ON THE RECEIPT OF REGISTRATION APPROVAL FOR TRIPTORELIN ACETATE MICROSPHERES FOR INJECTION (Announcement No.: 2023-037) issued by the Company on 11 May 2023.

The indication accepted this time is endometriosis. The drug is a gonadotropin-releasing hormone agonist for an intramuscular injection every month. Compared with ordinary triptorelin acetate injection, it has the characteristics of longer efficacy and reduced medication frequency, which can alleviate patients' pain and medication burden, as well as improve tolerance and accessibility of medication.

As at the date of this announcement, the accumulated direct investment expenses in research and development of Triptorelin Acetate Microspheres for Injection is approximately RMB 116.5682 million. RISK WARNING: According to the requirements of national laws and regulations related to drug registration, the above- mentioned drug will be transferred to the CDE for review and approval upon acceptance of the NMPA registration application, and the completion time and approval results are uncertain. The new indication can greatly expand the application scope of the drug, solve clinical needs, and further improve the market competitiveness of the drug.

The Company will fulfill its information disclosure obligations in a timely manner in accordance with the progress of research and development, and investors are kindly advised to make prudent decisions and pay attention to investment risks.